Tumor-Induced IL-6 Reprograms Host Metabolism to Suppress Anti-tumor Immunity

Cell Metabolism

Volumn 24, Issue 5, 2016, Pages 672-684

  Flint, Thomas R ^a   Janowitz, Tobias ^a,b   Connell, Claire M ^a,b   Roberts, Edward W ^c   Denton, Alice E ^a   Coll, Anthony P ^a   Jodrell, Duncan I ^a   Fearon, Douglas T ^a,d,e  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

cachexia; cancer immunology; cancer immunotherapy; glucocorticoids; hepatic metabolism; interleukin 6; ketogenesis; pancreatic cancer; PPARalpha; stress

Indexed keywords

CORTICOSTERONE; GLUCOCORTICOID; INTERLEUKIN 6; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CACHEXIA; CALORIC INTAKE; CALORIC RESTRICTION; CANCER IMMUNOTHERAPY; CANCER PATIENT; COLORECTAL CANCER; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; HORMONE RESPONSE; HUMAN; KETOGENESIS; MALE; METABOLIC STRESS; MOUSE; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; STRESS; TUMOR IMMUNITY; ADENOCARCINOMA; ANIMAL; BAGG ALBINO MOUSE; COMPLICATION; DEFICIENCY; IMMUNITY; IMMUNOLOGY; IMMUNOTHERAPY; KETOACIDOSIS; LIVER; METABOLISM; NUCLEAR REPROGRAMMING; PANCREAS TUMOR; PATHOLOGY; PHYSIOLOGICAL STRESS; SERODIAGNOSIS;

ADENOCARCINOMA; ANIMALS; CACHEXIA; CALORIC RESTRICTION; CELLULAR REPROGRAMMING; GLUCOCORTICOIDS; IMMUNITY; IMMUNOTHERAPY; INTERLEUKIN-6; KETOSIS; LIVER; MALE; MICE, INBRED BALB C; NEUTRALIZATION TESTS; PANCREATIC NEOPLASMS; STRESS, PHYSIOLOGICAL;

EID: 84994577858     PISSN: 15504131     EISSN: 19327420     Source Type: Journal    
DOI: 10.1016/j.cmet.2016.10.010     Document Type: Article

References (47)

1. Amiel, S.A., Archibald, H.R., Chusney, G., Williams, A.J., Gale, E.A., Ketone infusion lowers hormonal responses to hypoglycaemia: evidence for acute cerebral utilization of a non-glucose fuel. Clin. Sci. 81 (1991), 189–194.
2. Bachmann, J., Büchler, M.W., Friess, H., Martignoni, M.E., Cachexia in patients with chronic pancreatitis and pancreatic cancer: impact on survival and outcome. Nutr. Cancer 65 (2013), 827–833.
3. Brahmer, J.R., Tykodi, S.S., Chow, L.Q.M., Hwu, W.-J., Topalian, S.L., Hwu, P., Drake, C.G., Camacho, L.H., Kauh, J., Odunsi, K., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366 (2012), 2455–2465.
4. Cahill, G.F. Jr., Fuel metabolism in starvation. Annu. Rev. Nutr. 26 (2006), 1–22.
5. Chakravarthy, M.V., Pan, Z., Zhu, Y., Tordjman, K., Schneider, J.G., Coleman, T., Turk, J., Semenkovich, C.F., “New” hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis. Cell Metab. 1 (2005), 309–322.
6. Chang, C.-H., Qiu, J., O'Sullivan, D., Buck, M.D., Noguchi, T., Curtis, J.D., Chen, Q., Gindin, M., Gubin, M.M., van der Windt, G.J.W., et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162 (2015), 1229–1241.
7. Ellacott, K.L.J., Morton, G.J., Woods, S.C., Tso, P., Schwartz, M.W., Assessment of feeding behavior in laboratory mice. Cell Metab. 12 (2010), 10–17.
8. Fearon, K.C., McMillan, D.C., Preston, T., Winstanley, F.P., Cruickshank, A.M., Shenkin, A., Elevated circulating interleukin-6 is associated with an acute-phase response but reduced fixed hepatic protein synthesis in patients with cancer. Ann. Surg. 213 (1991), 26–31.
9. Fearon, K., Strasser, F., Anker, S.D., Bosaeus, I., Bruera, E., Fainsinger, R.L., Jatoi, A., Loprinzi, C., MacDonald, N., Mantovani, G., et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 12 (2011), 489–495.
10. Fearon, K.C.H., Glass, D.J., Guttridge, D.C., Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 16 (2012), 153–166.
11. Fearon, K., Arends, J., Baracos, V., Understanding the mechanisms and treatment options in cancer cachexia. Nat. Rev. Clin. Oncol. 10 (2013), 90–99.
12. Feig, C., Jones, J.O., Kraman, M., Wells, R.J.B., Deonarine, A., Chan, D.S., Connell, C.M., Roberts, E.W., Zhao, Q., Caballero, O.L., et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc. Natl. Acad. Sci. USA 110 (2013), 20212–20217.
13. Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313 (2006), 1960–1964.
14. Hingorani, S.R., Wang, L., Multani, A.S., Combs, C., Deramaudt, T.B., Hruban, R.H., Rustgi, A.K., Chang, S., Tuveson, D.A., Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7 (2005), 469–483.
15. Ho, P.-C., Bihuniak, J.D., Macintyre, A.N., Staron, M., Liu, X., Amezquita, R., Tsui, Y.-C., Cui, G., Micevic, G., Perales, J.C., et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell 162 (2015), 1217–1228.
16. Joyce, J.A., Fearon, D.T., T cell exclusion, immune privilege, and the tumor microenvironment. Science 348 (2015), 74–80.
17. Kalaany, N.Y., Sabatini, D.M., Tumours with PI3K activation are resistant to dietary restriction. Nature 458 (2009), 725–731.
18. Kamphorst, J.J., Cross, J.R., Fan, J., de Stanchina, E., Mathew, R., White, E.P., Thompson, C.B., Rabinowitz, J.D., Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. Proc. Natl. Acad. Sci. USA 110 (2013), 8882–8887.
19. Kersten, S., Seydoux, J., Peters, J.M., Gonzalez, F.J., Desvergne, B., Wahli, W., Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J. Clin. Invest. 103 (1999), 1489–1498.
20. Keusch, G.T., Farthing, M.J.G., Nutrition and infection. Annu. Rev. Nutr. 6 (1986), 131–154.
21. Kir, S., White, J.P., Kleiner, S., Kazak, L., Cohen, P., Baracos, V.E., Spiegelman, B.M., Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. Nature 513 (2014), 100–104.
22. Le, D.T., Wang-Gillam, A., Picozzi, V., Greten, T.F., Crocenzi, T., Springett, G., Morse, M., Zeh, H., Cohen, D., Fine, R.L., et al. Safety and survival with GVAX pancreas prime and Listeria Monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J. Clin. Oncol. 33 (2015), 1325–1333.
23. Mandard, S., Müller, M., Kersten, S., Peroxisome proliferator-activated receptor alpha target genes. Cell. Mol. Life Sci. 61 (2004), 393–416.
24. Masri, S., Papagiannakopoulos, T., Kinouchi, K., Liu, Y., Cervantes, M., Baldi, P., Jacks, T., Sassone-Corsi, P., Lung adenocarcinoma distally rewires hepatic circadian homeostasis. Cell 165 (2016), 896–909.
25. Mayers, J.R., Wu, C., Clish, C.B., Kraft, P., Torrence, M.E., Fiske, B.P., Yuan, C., Bao, Y., Townsend, M.K., Tworoger, S.S., et al. Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat. Med. 20 (2014), 1193–1198.
26. McGarry, J.D., Foster, D.W., The regulation of ketogenesis from octanoic acid. The role of the tricarboxylic acid cycle and fatty acid synthesis. J. Biol. Chem. 246 (1971), 1149–1159.
27. Mikucki, M.E., Fisher, D.T., Matsuzaki, J., Skitzki, J.J., Gaulin, N.B., Muhitch, J.B., Ku, A.W., Frelinger, J.G., Odunsi, K., Gajewski, T.F., et al. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat. Commun., 6, 2015, 7458.
28. Okada, S., Okusaka, T., Ishii, H., Kyogoku, A., Yoshimori, M., Kajimura, N., Yamaguchi, K., Kakizoe, T., Elevated serum interleukin-6 levels in patients with pancreatic cancer. Jpn. J. Clin. Oncol. 28 (1998), 12–15.
29. Olive, K.P., Jacobetz, M.A., Davidson, C.J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M.A., Caldwell, M.E., Allard, D., et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324 (2009), 1457–1461.
30. Park, E.J., Lee, J.H., Yu, G.-Y., He, G., Ali, S.R., Holzer, R.G., Österreicher, C.H., Takahashi, H., Karin, M., Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140 (2010), 197–208.
31. Petruzzelli, M., Schweiger, M., Schreiber, R., Campos-Olivas, R., Tsoli, M., Allen, J., Swarbrick, M., Rose-John, S., Rincon, M., Robertson, G., et al. A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metab. 20 (2014), 433–447.
32. Rhim, A.D., Oberstein, P.E., Thomas, D.H., Mirek, E.T., Palermo, C.F., Sastra, S.A., Dekleva, E.N., Saunders, T., Becerra, C.P., Tattersall, I.W., et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25 (2014), 735–747.
33. Roberts, E.W., Deonarine, A., Jones, J.O., Denton, A.E., Feig, C., Lyons, S.K., Espeli, M., Kraman, M., McKenna, B., Wells, R.J., et al. Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia. J. Exp. Med. 210 (2013), 1137–1151.
34. Rooney, M.S., Shukla, S.A., Wu, C.J., Getz, G., Hacohen, N., Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160 (2015), 48–61.
35. Royal, R.E., Levy, C., Turner, K., Mathur, A., Hughes, M., Kammula, U.S., Sherry, R.M., Topalian, S.L., Yang, J.C., Lowy, I., Rosenberg, S.A., Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J. Immunother. 33 (2010), 828–833.
36. Sengupta, S., Peterson, T.R., Laplante, M., Oh, S., Sabatini, D.M., mTORC1 controls fasting-induced ketogenesis and its modulation by ageing. Nature 468 (2010), 1100–1104.
37. Siegel, R., Naishadham, D., Jemal, A., Cancer statistics, 2012. CA Cancer J. Clin. 62 (2012), 10–29.
38. Staal-van den Brekel, A.J., Dentener, M.A., Schols, A.M., Buurman, W.A., Wouters, E.F., Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. J. Clin. Oncol. 13 (1995), 2600–2605.
39. Strassmann, G., Fong, M., Kenney, J.S., Jacob, C.O., Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J. Clin. Invest. 89 (1992), 1681–1684.
40. Tanaka, Y., Eda, H., Tanaka, T., Udagawa, T., Ishikawa, T., Horii, I., Ishitsuka, H., Kataoka, T., Taguchi, T., Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice. Cancer Res. 50 (1990), 2290–2295.
41. Tisdale, M.J., Mechanisms of cancer cachexia. Physiol. Rev. 89 (2009), 381–410.
42. Tuckermann, J.P., Kleiman, A., Moriggl, R., Spanbroek, R., Neumann, A., Illing, A., Clausen, B.E., Stride, B., Förster, I., Habenicht, A.J.R., et al. Macrophages and neutrophils are the targets for immune suppression by glucocorticoids in contact allergy. J. Clin. Invest. 117 (2007), 1381–1390.
43. Tumeh, P.C., Harview, C.L., Yearley, J.H., Shintaku, I.P., Taylor, E.J.M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515 (2014), 568–571.
44. Wang, J., Dunn, A.J., Mouse interleukin-6 stimulates the HPA axis and increases brain tryptophan and serotonin metabolism. Neurochem. Int. 33 (1998), 143–154.
45. Zelenay, S., van der Veen, A.G., Böttcher, J.P., Snelgrove, K.J., Rogers, N., Acton, S.E., Chakravarty, P., Girotti, M.R., Marais, R., Quezada, S.A., et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell 162 (2015), 1257–1270.
46. Zhou, X., Wang, J.L., Lu, J., Song, Y., Kwak, K.S., Jiao, Q., Rosenfeld, R., Chen, Q., Boone, T., Simonet, W.S., et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 142 (2010), 531–543.
47. Zhu, Y., Knolhoff, B.L., Meyer, M.A., Nywening, T.M., West, B.L., Luo, J., Wang-Gillam, A., Goedegebuure, S.P., Linehan, D.C., DeNardo, D.G., CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 74 (2014), 5057–5069.